Zacks Research Issues Negative Outlook for LLY Earnings

Eli Lilly and Company (NYSE:LLY) – Zacks Research reduced their Q4 2025 earnings estimates for shares of Eli Lilly and Company in a research report issued to clients and investors on Thursday, August 28th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $6.83 for the quarter, down from their previous forecast of $6.97. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company’s Q1 2026 earnings at $6.22 EPS, FY2026 earnings at $29.21 EPS and FY2027 earnings at $34.91 EPS.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS.

Several other research analysts have also recently weighed in on the stock. Cantor Fitzgerald dropped their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 13th. Leerink Partners reiterated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Guggenheim dropped their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $950.17.

Eli Lilly and Company Trading Up 0.3%

Shares of Eli Lilly and Company stock opened at $734.57 on Monday. The company’s fifty day simple moving average is $747.03 and its 200-day simple moving average is $783.75. The stock has a market capitalization of $695.24 billion, a PE ratio of 48.01, a P/E/G ratio of 1.02 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $969.65. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company’s payout ratio is presently 39.22%.

Insiders Place Their Bets

In other news, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds have recently added to or reduced their stakes in LLY. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Orion Capital Management LLC grew its stake in Eli Lilly and Company by 2.5% in the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company’s stock worth $1,243,000 after acquiring an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG grew its stake in Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company’s stock worth $49,993,000 after acquiring an additional 2,568 shares in the last quarter. Finally, Breed s Hill Capital LLC grew its stake in Eli Lilly and Company by 212.0% in the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company’s stock worth $1,101,000 after acquiring an additional 969 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.